title: Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.
authors.forename: L
authors.initials: L
authors.lastname: Cavanna
authors.forename: M
authors.initials: M
authors.lastname: Di Stasi
authors.forename: F
authors.initials: F
authors.lastname: Fornari
authors.forename: G
authors.initials: G
authors.lastname: Civardi
authors.forename: G
authors.initials: G
authors.lastname: Sbolli
authors.forename: M
authors.initials: M
authors.lastname: Moretto
authors.forename: L
authors.initials: L
authors.lastname: Buscarini
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local
chemical_list: D003561:Cytarabine; D015255:Idarubicin